COVID-19 trials registries data warehouse

http://en.irct.ir/trial/49282

Dr. Teamur Aghamolaei

research@hums.ac.ir

2020-08-09

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

All definitively positive COVID-19 patients with Hb≤9. Having at least one of the severe symptoms of COVID-19, including tachypnea (breathing rate> 30 beats per minute), hypoxemia (O2 ≤93 saturation, the partial pressure ratio of arterial oxygen <300), Lung infiltration (> 50% of lung field within 24 to 48 hours), progressive lymphopenia, LDH>245 U/I, CRP>100

Patients with a history of coagulopathy Patients with a history of thrombosis Patients with a history of deep vein thrombosis Patients with a history of chronic lung disease Patients with a history of diabetes mellitus Patients with weakened immune systems Patients with a history of end stage renal disease Patients with liver disease Patients with a history of taking oral contraceptive pills (OCPs) Patients with systolic blood pressure greater than 160 mmHg Patients with diastolic blood pressure greater than 90 mmHg Patients over 65 years of age Patients with erythropoietin above 500 Patients with a history of myocardial infarction or unstable angina Patients with a history of malignancy

2

Bandare-abbas University of Medical Sciences

0

65

Iran

Severe disease at enrollment

6: Severe disease at enrollment

20

Respiratory rate Oxygen saturation state and arterial oxygen partial pressure ratio Lung infiltration status LDH level's CRP level's Lymphocyte count Endogenous erythropoietin level's Patients' blood pressure

Phase 2

[{"arm_notes": "", "treatment_id": 1076, "treatment_name": "Recombinant erythropoietin", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]